



## CLINICAL GUIDELINE

# Progestogen-only Injectable Contraception

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.

If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

<b>Version Number:</b>	1
<b>Does this version include changes to clinical advice:</b>	N/A
<b>Date Approved:</b>	1 <sup>st</sup> March 2025
<b>Date of Next Review:</b>	31 <sup>st</sup> March 2027
<b>Lead Author:</b>	Kay McAllister
<b>Approval Group:</b>	Sandyford Governance Group
<b>Guideline ID number:</b>	1265

### Important Note:

The online version of this document is the only version that is maintained. Any printed copies should therefore be viewed as 'Uncontrolled' and as such, may not necessarily contain the latest updates and amendments.

## PROGESTOGEN-ONLY INJECTABLE CONTRACEPTION

### What's New

**The website provided by Pfizer to help patients self-administer Sayana is currently unavailable**

### Key Points:

Sandyford no longer sees patients for repeat Sayana injections. Sandyford staff can facilitate self-injecting on the first appointment, then issue a one year supply. However this would be dependent on the service it was commenced at. Client should be seen in a Nurse list.

This guideline will refer to the term 'woman', 'she' or 'herself' in accordance with the Women's Health Plan Scotland, and will encompass all those who require access to women's health and/or reproductive services

### Mode of Action

The primary mode of action is to prevent ovulation, supplemented by contraceptive actions at the endometrial and cervical mucus level.

### Dosing Interval

The recommended dosing interval for IM DMPA (Depo-Provera®) and SC DMPA (Sayana Press®) is **13 weeks**. This is outside the product licence for Depo-Provera®.

DMPA may be administered up to 14 weeks from the last injection without the need for additional contraceptive precautions (outside product licence for Depo-Provera®).

### Efficacy

Perfect use failure rate is 0.2% in the first year of use.

Injectable contraceptives are long acting reversible contraceptives. Typical use failure rates are lower than failure rates for oral contraceptives. However, injectable contraceptives are less cost-effective than the implant and intrauterine methods because users are required to return more frequently.

**Administration**

Shake syringe vigorously

**SC DMPA**

- Activate the injector according to the manufacturer's instructions ([www.medicines.org.uk/emc](http://www.medicines.org.uk/emc))
- Inject into upper anterior thigh or abdomen
- Point needle downwards (towards the floor) and inject over 5-7 seconds
- Licensed for self-administration and can be offered routinely by staff trained to instruct patients

**IM DMPA**

- IM injection into gluteus maximus or other muscle e.g. deltoid
  - IM administration into ventrogluteal site. Is the preferred site as it reduces the risk of superficial injection and sciatic nerve injury.
  - If not yet trained in ventrogluteal injection, or if client requests, the dorsogluteal site (upper outer quadrant of buttock) or deltoid should be used.


**Common Side Effects**

- Change in menstrual pattern
- Delay in return of fertility. (Median time to ovulation is 6 to 7 months following the preceding injection i.e: 3 – 4 months following cessation of therapy).
- Weight gain
- Injection site reactions (more common with s.c. than i.m. administration)

**Less Common Adverse Effects**

- Prolonged or very heavy bleeding – history and examination must be taken to exclude gynaecology pathology (eg: pelvic, infection, miscarriage).
- Anaphylaxis
- Galactorrhoea
- Possible small increased relative risk of breast cancer and cervical cancer
- Loss of bone mineral density (see below)

### Action for Persistent Bleeding



There is no evidence that reducing the injection interval improves bleeding but the interval can be reduced to 10 weeks if the patient wishes early repeat injections.

## **Assessment of Client Suitability**

### **History**

- Clinical history taking and examination allow an assessment of medical eligibility for DMPA use (UK Medical Eligibility Criteria: <http://mag.digitalpc.co.uk/fvx/fsrh/ukmec/2016/>). In this context the history should include: relevant social and sexual history (to assess risk of sexually transmitted infections – STIs), medical, family and drug history as well as details of reproductive health and previous contraceptive use.
- Risk factors for osteoporosis should be assessed and alternative contraceptive choices discussed as appropriate.

### **Patient Self Administration of Sayana Press**

New and existing Depo-Provera users aged between 18 and 50. . Also must be willing and able to self-administer Sayana Press. See GP for further supply of Sayana.

### **Examination**

- BMI should be noted prior to commencement of injectable contraception
- Pelvic examination and cervical cytology if indicated

### **Documentation**

- The full visit history should be completed or updated as required, including osteoporosis risk factors
- Written method information including contact number is given to client
- Prescription is recorded and dated
- Site of injection, batch number and expiry date of medication recorded
- Record date when injection is next due
- Nurse supplying where appropriate under patient group direction
- GP notified of prescription, if permission is given for correspondence

**Management & Timing Of First Injection**

<p>General initiation</p>	<p>Ideally, first injection should occur between Days 1–5 (inclusive) of a normal menstrual cycle. No additional contraception is required.</p> <p>Injections may also be initiated at any other time in the menstrual cycle if the clinician is reasonably certain that the woman is not pregnant and that there is no risk of conception.</p> <p>Additional contraception (barrier method or abstinence) should be advised for 7 days after initiation.</p> <p>If the woman is amenorrhoeic, the clinician must be reasonably certain that the woman is not pregnant and there is no risk of conception. Additional contraception should be used for 7 days.</p>
<p>Post-partum</p>	<p>Progestogen-only injectables may be initiated up to and including Day 21 postpartum with immediate contraceptive cover. If initiated after Day 21 then condoms or abstinence is advised for 7 days. Medroxyprogesterone is safe to use during breast-feeding.</p>
<p>Following miscarriage or termination</p>	<p>Initiate on day of surgical or second part of medical abortion or immediately following miscarriage: No additional contraception is required.</p> <p>If started &gt;5 days after abortion or miscarriage, additional contraception is required for 7 days.</p>
<p>Switching from CHC, PO implant or POP</p>	<p>Can be initiated immediately if method has been used consistently and correctly or if the clinician is reasonably certain that the woman is not pregnant and that there has been no risk of conception.</p> <p>No additional contraception is needed.</p>
<p>Switching from PO injectable</p>	<p>If the woman's previous method was another injectable, she should have the injection before or at the time the next injection was due. No additional contraception is needed.</p>
<p>Switching from IUS</p>	<p>Can be initiated immediately if the LNG-IUS was used consistently and correctly or if the clinician is reasonably sure that the woman is not pregnant. As bleeding with the LNG-IUS may not reflect ovarian activity, the LNG-IUS should be continued for at least 7 days.</p>
<p>Switching from IUD</p>	<p>Can be initiated immediately if the IUD was used consistently and correctly or if the clinician is reasonably sure that the woman is not pregnant.</p>

	The IUD should be continued for at least 7 days unless the first injection occurs between Days 1–5 (inclusive) of a normal menstrual cycle.
Switching from barrier method	Can be initiated immediately if barrier method has been used consistently and correctly or if the clinician is reasonably certain that the woman is not pregnant and that there is no risk of conception. If the woman is amenorrhoeic or it has been more than 5 days since menstrual bleeding started, additional contraception should be continued for 7 days.
Quick starting after oral EC or in other situations in which pregnancy cannot be excluded	<p>DMPA should only be quick started in the absence of acceptable alternatives.</p> <p>Quick starting after Levonorgestrel EC: give DMPA immediately and advise condoms for 7 days.</p> <p>Quick starting after Ulipristal EC: wait for at least 5 days following EC before administering DMPA. Advise condoms for a further 7 days (12 days of condom use in total)</p> <p><b><i>*patient requires a pregnancy test 3 weeks after last UPSI</i></b></p>

\*see Appendix 2

### **DMPA and Bone Mineral Density**

Patient using DMPA contraception have a small reduction in bone mineral density (BMD) while using this method of contraception, which may be at least partly reversible on discontinuation. It is not known whether this increases the risk of osteoporosis in later life. The effect on BMD may be most marked in adolescents, who have yet to achieve their peak bone mass. For adolescent patient, the MRHA recommends that DMPA is prescribed as first line contraception only after other methods have been discussed and deemed unsuitable or unacceptable.

See flow chart below for suggested management in patient who wish to continue with this method of contraception for more than 2 years.

Gonadotrophin checks or oestrogen replacement are not advised.


### **Long Term Use of DMPA > 2 Years**

DMPA >2 years regardless of bleeding pattern

- Discuss effects of DMPA on bone density and uncertainty about risk of later osteoporosis/fracture
- Review risk factors for osteoporosis: alcohol, exercise, diet, smoking, family history, medical conditions, e.g. Crohn's or drug use, e.g. steroids
- Discuss alternative forms of contraception.
- Document discussion and client's choice in notes

Continue client contraceptive method of choice  
Review indications, risk factors, alternatives  
every 2 years

**Delayed Follow Up Visit > 13 weeks**



## References

FSRH. Progestogen-only injectable contraception. December 2014, amended October 2019

<http://www.fsrh.org/pdfs/CEUGuidanceProgestogenOnlyInjectables.pdf>

[accessed March 2025]

FSRH. UK Medical eligibility criteria for contraceptive use. July 2016.

<http://mag.digitalpc.co.uk/fvx/fsrh/ukmec/2016/>

[accessed March 2025]

FSRH. Problematic bleeding with using hormonal contraception. July 2015.

<http://www.fsrh.org/pdfs/CEUGuidanceProblematicBleedingHormonalContraception.pdf>

[accessed March 2025]

FSRH Drug Interactions with Hormonal Contraception January 2017

<http://www.fsrh.org/pdfs/CEUGuidanceDrugInteractionsHormonal.pdf>

[accessed March 2025]

FSRH New Product Review. Subcutaneous medroxyprogesterone acetate. June 2013.

<http://www.fsrh.org/pdfs/CEUProductReviewSayana.pdf>

[accessed March 2025]

FSRH Quick Starting Contraception April 2017

<http://www.fsrh.org/pdfs/CEUGuidanceQuickStartingContraception.pdf>

[accessed March 2025]

## APPENDIX 1

### **Self Administration of Sayana Press**

**NOT** suitable for:

- Clients under 18
- Those not proficient in the English language

#### **Consultation 1**

The clinician should give the first injection while instructing the patient on its use.

A) .

#### **Consultation 2**

- B) Check if they have any questions/concerns
  - C) Patient self-administers Sayana Press under nurse supervision. If the patient wishes to continue with Sayana Press a prescription for three further doses can be dispensed.
  - D) Give patient a
    - sharps bin and verbal instructions on use,
    - date for annual review (Nurse 20 mins booked appointment)
- Sharps canisters should be locked and returned to Sandyford Services.
- E) .

#### **Consultation 3**

We no longer have an annual review. Direct this to the GP.

While rare, anaphylactic reaction is possible with both first and subsequent exposure to Sayana press. It is therefore recommended that users are advised to ensure there is a competent adult present at the time of self-administration who is aware that they should call for emergency help at the time of the onset of any relevant symptoms

## APPENDIX 2

### Check List for Quick Starting Hormonal Contraception

If risk of pregnancy cannot be reasonably excluded, the contraceptive provider should ensure that the woman is:

- Likely to continue to be at risk of pregnancy or that she has expressed a preference to begin contraception immediately.
- Aware that there is a possibility of pregnancy.
- Informed that there is a theoretical risk from foetal exposure to contraceptive hormones but most evidence indicates no harm.
- Aware that pregnancy cannot be excluded until she has had a pregnancy test no sooner than 3 weeks after the last episode of unprotected sexual intercourse.
- Provided with a pregnancy testing kit or informed of alternative options for pregnancy testing, including local and providers of free testing. The YP is given a test advice sheet and asked to follow instructions. Add to YP Virtual diary on the next Tuesday after the test is due. The Home Pregnancy Test Advice Sheet can be found on the YP Team Folder.
- Given advice on additional contraceptive precautions.
- Offered a supply of condoms or informed of local providers of condoms.
- Advised to return if there are any concerns or problems with her contraception.